Mergers and Acquisitions

J&J to buy Swiss biopharma firm Actelion for $30 billion

Johnson & Johnson is buying Swiss biopharmaceutical company Actelion Ltd. for about $30 billion, handing the U.S.-based health care products giant a chance to boost its presence in innovative biotech treatments.

J&J to buy Swiss biopharma firm Actelion for $30 billion

Johnson & Johnson is buying Swiss biopharmaceutical company Actelion Ltd. for about $30 billion, handing the U.S.-based health care products giant a chance to boost its presence in innovative biotech treatments.

Speculation Builds on a Verizon-Charter Tie-up, No Offer Made

U.S. cable company Charter Communication Inc shares rose as much as 10 percent on Thursday after the Wall Street Journal reported a preliminary approach by Verizon Communications Inc about a tie-up, but Reuters sources said no proposal was made.

Speculation Builds on a Verizon-Charter Tie-up, No Offer Made

U.S. cable company Charter Communication Inc shares rose as much as 10 percent on Thursday after the Wall Street Journal reported a preliminary approach by Verizon Communications Inc about a tie-up, but Reuters sources said no proposal was made.